| Document |
Document Title |
|
JP2010522169A |
Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective...
|
|
JP4494207B2 |
Fluorosilicone fluids useful as high-density fluid ocular tamponades and methods of producing, purifying and using the fluorosilicone fluids in an ocular surgical procedure for retinal treatment.
|
|
JP4486823B2 |
Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory disea...
|
|
JP2010130900A |
To provide a novel oligonucleotide which has a higher binding ability to NF-κB than that of a conventional oligonucleotide decoy to NF-κB and is useful as NF-κB decoy, and to provide a medicinal use thereof. The oligonucleotide is a c...
|
|
JP2010132696A |
To provide solutions including multiple active agents to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease the intraocular pressure in operation, wherein the solutions are prepared for intraocu...
|
|
JP2010131435A |
To provide an anti-adhesion material for preventing adhesion after an operation.A honeycomb film made of a biodegradable polymer having biodegradability, excelling in handleability and stably exhibiting an excellent anti-adhesion effect ...
|
|
JP4480131B2 |
An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is dislosed. The compositions comprise combinations of sodium hyaluoronate and chondroiting sulfate and e...
|
|
JP4475960B2 |
The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use...
|
|
JP4472526B2 |
The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275. Such variants exhibit increased clott...
|
|
JP2010116411A |
To provide organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.The organic molecules are compounds represented by the formula in the figure...
|
|
JP2010518172A |
Glutamine source formulations that have release profiles that provide for sustained release via intraperitoneal administration of glutamine reduces post-operative adhesion formation.
|
|
JP4467549B2 |
IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
|
|
JP4469424B2 |
A compound of the formulawherein the substituents are defined as in the specification and their pharmaceutically acceptable salts having NOS and ROS activity.
|
|
JPWO2008096722A1 |
The present invention is a cerebral surface vascular bleeding inhibitor consisting of an aqueous solution containing sodium ions 120 to 160 mEq / L, calcium ions 1 to 5 mEq / L, and chlorine ions 75 to 165 mEq / L; and potassium ions 1 t...
|
|
JP2010514707A |
A use of a hypertonic solution composition in manufacturing medicaments used during the perioperative period for promoting wound healing, said composition consists of 1.5%-6.9% (w/v) of one or more substances selected from sodium chlorid...
|
|
JP4458852B2 |
The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester...
|
|
JP4446145B2 |
A benzamidine derivative of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an effect of inhibiting the blood coagulation based on their excellent effect of inhibiting activated blood-coagulation...
|
|
JP4447640B2 |
The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and conven...
|
|
JP2010047534A |
To provide an enzyme-responsive lipid peptide which produces a lipid peptide capable of becoming a hydrogel by forming a self aggregate in response to a peptidase.The lipid peptide has a structure represented by the formula: lipid peptid...
|
|
JP2010043094A |
To provide methods which can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial diseases by administration of nicotine or other nicotine receptor agonists.The meth...
|
|
JP2010035744A |
To provide an adheshion preventive material capable of being used in regions other than an abdominal cavity.The adheshion preventive material is formed of hydrogel of polysaccharide derivative and increases the complex elastic modulus ob...
|
|
JP4418535B2 |
Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel ...
|
|
JP2010504306A |
There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound.
|
|
JP2010502560A |
Methods for performing percutaneous coronary intervention in a patient in need thereof comprising administering intravenously a bolus comprising an effective amount of enoxaparin sodium to the patient after sheath insertion and prior to ...
|
|
JP2010017548A |
To provide a combination for administration to tissue including the submucosa tissue of a polyp.The combination includes: a composition which includes a biocompatible small molecule crosslinker having n crosslinker functional groups and ...
|
|
JP2010013482A |
To provide a medicine for treating multiple myeloma.The medicine for treating multiple myeloma in a patient includes cyclopropane carboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methane sulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-iso-i...
|
|
JP4394882B2 |
This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.
|
|
JP2009298795A |
To prepare a new controlled-release type pharmaceutical formulation making a controlled delivery of a specific pharmaceutical, and a method for using the formulation in treating or preventing thrombosis.The new controlled-release type ph...
|
|
JP4383543B2 |
The present invention uses and implants a composition under the area of the skin where wrinkles occur, said composition being substantially non-absorbable and not subject to rejection or allergic reaction. The composition of the present ...
|
|
JP4378442B2 |
|
|
JP2009280597A |
To provide a composition for treating psoriasis without accompanying adverse effects.A use of a therapeutically effective amount of fucan in producing therapeutic agent is provided. The therapeutic agent is produced in a slow releasing p...
|
|
JP2009273468A |
To provide a specific serine proteinase inhibitor because uncontrolled tissue damage and inflammation by increased predetermined proteinase activity caused by the increase of absorption of a peptide-based proteinase inhibitor occur somet...
|
|
JP2009539988A |
The present invention relates to compounds of formula IA-i useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the comp...
|
|
JP2009539832A |
Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared....
|
|
JP2009539873A |
The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. Th...
|
|
JP2009539773A |
The invention provides compounds of formula I: or pharmaceutically salts thereof, where R 1 , R 2 and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as A...
|
|
JP4366081B2 |
The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.
|
|
JP4361728B2 |
The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmac...
|
|
JP2009537504A |
The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39 -methylrapamyci...
|
|
JP2009536637A |
The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularl...
|
|
JP2009535018A |
The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of...
|
|
JP2009534292A |
The present invention provides a solid pharmaceutical composition containing (a) a core containing a compound represented by the formula (I) wherein R1is an optionally substituted, monocyclic nitrogen-containing heterocyclic group having...
|
|
JP2009534388A |
Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
|
|
JP2009215311A |
To provide a carbonyl compound to deliver CO to a physiological object or target for giving physiological effects.The present invention provides any of following compounds from (1) to (4): (1) CO released by dissociation of the metal car...
|
|
JP2009533455A |
The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellul...
|
|
JP2009532038A |
The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to a transcription factor modulator comprising (i) a pharmaceutically-effective amou...
|
|
JP2009532475A |
The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using t...
|
|
JP2009531367A |
The present disclosure relates to compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment.
|
|
JP2009197032A |
To provide a consistent and effective method of immunizing cancer patients.This invention provides a method of overcoming immune suppression by inducing production of untreated T cell and recovered T cell immunity, that is, recovery of i...
|
|
JP2009191072A |
To provide a method for treating and preventing certain types of cancers, including primary and metastatic cancers, as well as cancers that are refractory or resistant to conventional chemotherapy.Provided is the method of preventing or ...
|
